Eiger BioPharmaceuticals, Inc. EIGRQ

8.50 0.00 0.00% as of 1 Oct
Market cap
$2.6M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '23 Sep '23 Jun '23 Mar '23 Older periods
ROE
(367.00%) (225.93%) (161.95%) (146.28%)

+8 more TTM periods

ROA
(94.31%) (86.91%) (81.11%) (76.75%)
ROIC
(3,674.55%) 0.00% (2,469.33%) (14,894.98%)
Return on Tangible Assets
505.89% (223.45%) (175.56%) (131.47%)
Average Days of Receivables
38.92 32.88 87.59 95.13
Free Cash Flow per Share
(50.67) (56.44) (60.61) (60.62)
Free Cash Flow
(74.78) (83.30) (89.41) (89.11)
Capital Expenditures
(0.23) (0.46) (0.56) (0.56)
Piotroski F-Score
3.00 3.00 2.00 3.00
Other line items
Cash ROIC
(143.08%) (105.19%) (81.08%) (58.67%)
Accounts Receivable Turnover
9.19 7.76 6.51 4.83
Accounts Payable Turnover
0.00 0.03 0.19 0.18
Inventory Turnover
0.01 0.14 0.70 0.51
Average Days of Payables
32,165.63 6,616.31 1,304.40 2,345.89
Days of Inventory on Hand
23,664.17 1,504.94 289.57 1,056.03
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
395.18% 472.10% 496.53% 498.76%
Selling, General and Administrative Expense of Revenue
159.79% 196.39% 195.81% 213.06%
Share Based Compensation of Revenue
31.75% 42.04% 47.47% 59.03%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.99 0.96 0.93 0.91
Depreciation/Fixed assets
(1.33) (1.14) (0.50) 0.34
Capex/Depreciation
0.28 0.59 1.51 (2.05)
Revenue per Share
10.69 9.94 10.49 10.16
Operating CF per Share
(50.51) (56.13) (60.23) (60.24)
Capex per Share
(0.16) (0.31) (0.38) (0.38)
Capex to Sales
0.01 0.03 0.04 0.04
Net Profit Margin
(475.26%) (590.80%) (618.36%) (649.19%)

Fold the line items

Columns are period end dates